Trial · NCT07888530
Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07888530, Not yet recruiting, Hrain Biotechnology Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Trials, record NCT07888530. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07888530
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- NCT number
- NCT07888530
- Status
- Not yet recruiting
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Hrain Biotechnology Co., Ltd.
- Conditions
- B-Cell Non-Hodgkin Lymphoma (NHL)
- Interventions
- Ranicabtagene Autoleucel Injection
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) after administration [Effectiveness Metrics] | 5 years post infusion | The time from Ranicabtagene Autoleucel Injection infusion to death from any cause. |
| Secondary | Overall response rate (ORR) [Effectiveness Metrics] | 5 years post infusion | Percentage of participants with CR or PR. |
| Secondary | Complete response rate (CRR) [Effectiveness Metrics] | 5 years post infusion | Percentage of participants with CR. |
| Secondary | Duration of remission (DOR) [Effectiveness Metrics] | 5 years post infusion | The time from the first tumor assessment showing CR or PR to the first assessment of disease progression or death from any cause. |
| Secondary | Progression free survival (PFS) [Effectiveness Metrics] | 5 years post infusion | The time from Ranicabtagene Autoleucel Injection infusion to the first assessment of tumor progression or death from any cause. |
| Secondary | Cytokine release syndrome (CRS) [Safety Indicators] | 5 years post infusion | Percentage of participants with CRS. |
| Secondary | Immune effector cell-associated neurotoxicity syndrome (ICANS) [Safety Indicators] | 5 years post infusion | Percentage of participants with ICANS. |
| Secondary | Severe infection [Safety Indicators] | 5 years post infusion | Percentage of participants with severe infection. |
| Secondary | B cell aplasia and hypogammaglobulinemia [Safety Indicators] | 5 years post infusion | Percentage of participants with B cell aplasia and hypogammaglobulinemia. |
| Secondary | Prolonged cytopenia [Safety Indicators] | 5 years post infusion | Percentage of participants with prolonged cytopenia. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07888530
GET https://conductscience.org/api/trials/v1/NCT07888530/registered